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MicroRNAs (miRNAs) can influence lineage choice or
affect critical developmental checkpoints during
hematopoiesis. We examined the role of the p53-
induced microRNA miR-34a in hematopoiesis by
gain-of-function analysis in murine bone marrow.
Constitutive expression of miR-34a led to a block in
B cell development at the pro-B-cell-to-pre-B-cell
transition, leading to a reduction in mature B cells.
This block appeared to be mediated primarily by
inhibited expression of the transcription factor
Foxp1. Foxp1 was a direct target of miR-34a in
a 30-untranslated region (UTR)-dependent fashion.
Knockdown of Foxp1 by siRNA recapitulated the B
cell developmental phenotype induced by miR-34a,
whereas cotransduction of Foxp1 lacking its 30 UTR
with miR-34a rescued B cell maturation. Knockdown
of miR-34a resulted in increased amounts of Foxp1
and mature B cells. These findings identify a role
for miR-34a in connecting the p53 network with
suppression of Foxp1, a known B cell oncogene.
INTRODUCTION
Antigen-independent B cell development from hematopoietic
stem and progenitor cells is a complex process, closely coordi-
nated with the generation of functional antigen receptors (Hardy
and Hayakawa, 2001). B cells are the end product of an ordered
series of developmental steps punctuated by checkpoints after
the rearrangement of the immunoglobulin heavy (IgH) and light
chain (IgL) loci. Defined stages of committed B cell precursors
include pro-B cells, during which B cells rearrange IgH, pre-B
cells, during which IgL is rearranged, and finally immature and
mature B cells expressing variable amounts of surface immuno-
globulin (IgM). A complex sequence of molecular events orches-
trates successful V(D)J rearrangement in B cells. It includes the
activation of several transcription factors, notably PU.1, E2a,
Ebf, and Pax5 (Busslinger, 2004). A recent addition to the list
of transcription factors required for early B cell development is
Foxp1 (Hu et al., 2006). With a recombination activating gene-248 Immunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc.(Rag2) complementation system, loss of this transcription factor
was found to cause a block in early B cell development. Further-
more, a functional role in coordinating the development of B cells
was suggested by Foxp1’s ability to bind to enhancer elements
within the Rag gene loci (Hu et al., 2006). Foxp1 is a forkhead
transcription factor with functions in tissue and cell-type specific
gene expression and its targeted deletion is lethal in embryogen-
esis, mainly because of cardiac defects (Shu et al., 2001; Wang
et al., 2004).
During B cell development, multiple checkpoints follow the
rearrangement of the immunoglobulin loci (Meffre et al., 2000)
that are partially dependent on p53 (encoded by Trp53).
Trp53/ mice show decreased apoptosis of pro-B cells, as
well as accumulation of pre-B cells and immature B cells (Lu
and Osmond, 2000). Additionally, in SCID mice, deficiency of
Trp53 leads to a massive accumulation of pro-B cells (Guidos
et al., 1996). Presumably, such cells would normally undergo
apoptosis as consequence of p53’s action in coordinating the
response of cells to DNA damage. The apoptosis of pro-B cells
depends on the ratio of proapoptotic Bax to the prosurvival Bcl-2
protein, and this ratio is disrupted in Trp53/ mice.
Recently, the miR-34 family of miRNAs was discovered to be
transcriptionally induced by p53 (Chang et al., 2007; He et al.,
2007; Raver-Shapira et al., 2007). These miRNAs act by sup-
pressing genes important in cell cycle progression, antiapoptotic
functions, and regulation of cell growth. As might be expected,
expression of these miRNAs is altered in a broad range of
cancers, with the most common scenario being one in which
both p53 and miR-34 are downregulated (reviewed in Hermek-
ing, 2010). In cancers of the hematopoietic system, profiling
studies have suggested a role for one member of the miR-34
family, miR-34a, in chronic lymphocytic leukemia and acute
myeloid leukemia (Isken et al., 2008; Mraz et al., 2009; Zenz
et al., 2009). In the case of chronic lymphocytic leukemia,
miR-34a alterations have been described both in association
with and independent of p53 deletions.
A role for miR-34a in normal hematopoiesis has not yet been
defined. Such a role has been described for many miRNAs,
with multiple recent studies describing the impact of miRNAs
on lineage determinations during hematopoietic differentiation
(reviewed in Baltimore et al., 2008). Indeed, these were some
of the first functions described for miRNAs in mammalian
systems, with miR-181 promoting B lineage cell differentiation
MGP-34a
GFPLTR 34a LTRPGK-Puro
M
G
P
M
G
P
-
34
a
60
20
Ve
cto
r
mi
R-
34
a
0.1
1
10
100
1000
m
iR
-3
4a
 e
xp
re
ss
io
n
(a
rb
itr
ar
y 
un
its
)
Ve
cto
r
mi
R-
34
a
0
20
40
60
80
100
M
ye
lo
id
 c
el
ls
(%
 o
f G
FP
+  
ce
lls
)
Ve
cto
r
mi
R-
34
a
0
5
10
15
E
ry
th
ro
id
 c
el
ls
(%
 o
f G
FP
+  
ce
lls
)
Ve
cto
r
mi
R-
34
a
0
1
2
3
4
5
T-
ce
lls
 (%
 o
f G
FP
+  
ce
lls
)
*
Ve
cto
r
mi
R-
34
a
0
5
10
15
M
at
ur
e 
B 
ce
lls
(%
 o
f G
FP
+  
ce
lls
)
*D E F
A
EtBr
B
Vector miR-34a
C
HG
GFPC
el
l n
um
be
r
Figure 1. ConstitutiveExpressionofmiR-34a
in the Bone Marrow Compartment Leads to
a Decrease in Mature B Lymphocytes
(A) Schematic representation of the MSCV-based
retroviral vector used to express miR-34a, based
on the previously described MGP vector (O’Con-
nell et al., 2009).
(B) Expression of pre-miR-34a (60 nt) and mature
miR-34a (20 nt) was assayed by RNA blotting.
The bottom panel shows Ethidium bromide stain-
ing (EtBr) to confirm equal loading.
(C) Analysis of GFP expression in bone marrow
2 months after retroviral transduction and
transfer.
(D) Expression of miR-34a in bone marrow by RT-
qPCR, normalized to 5S. Individual dots represent
one mouse; the lines show the mean of miR-34a
expression in individual mice from two indepen-
dent experiments (n = 8 for each group; t test,
p = 0.009).
(E) Bone marrow mature B cells detected as
a percentage of GFP+ cells by flow cytometry in
mice expressing vector alone or miR-34a are
shown. An individual dot represents one mouse;
the lines show the mean percentage of B cells in
individual mice from three independent experi-
ments (n = 10 for each group; t test, p = 0.0093).
(F–H) Flow cytometric analyses for myeloid
cells (defined as GFP+CD11b+), erythroid cells
(GFP+Ter119+), and T cells (GFP+CD33+) are
shown. Individual dots represent percent of
myeloid cells (F), erythroid cells (G), and T cells
(H) in the bone marrow of an individual mouse,
and the lines show the mean percent of each cell
type in mice from three independent experiments
(n = 9 for each group; t test, n.s.).
Immunity
mir-34a and Foxp1 in B Cell Development(Chen et al., 2004). The functional effects of miRNAs may
depend on the regulation of a few critical factors that control
gene expression, thereby affecting lineage choice (Xiao and
Rajewsky, 2009). The range of targets ascribed to miR-34a
suggests that it might have a role in the regulation of hematopoi-
etic development. In fact, a role in B cell development was
hypothesized after the demonstration that Bcl-2 is a direct
target of miR-34a regulation (Bommer et al., 2007). It was
particularly striking that an imbalance between Bax and Bcl-2
could lead to a defect in pro-B cell apoptosis in Trp53/ mice.
Here, we attempt to understand how miR-34a may be involved
in hematopoiesis. We found that constitutive expression of
miR-34a causes a partial block in B cell development, whereas
its knockdown resulted in increased B cells. The key mediator
of the miR-34a effect appears to be the Foxp1 transcription
factor, which we found to be a direct target of miR-34a.
Knockdown of Foxp1 with an siRNA mimicked the effect of
overexpression of miR-34a. Thus miR-34a appears to play an
important role in the orchestration of B cell development in
the mouse.RESULTS
Constitutive Expression of miR-34a in the Bone Marrow
Leads to a Decrease of B Lymphocytes
To explore the role of miR-34a in hematopoietic differentiation,
we designed retroviral vectors that express the microRNA. The
vector coexpresses miR-34a and green fluorescent protein
(GFP) and exploits the miR-155 format vector that we have
previously utilized successfully to give strong expression of
microRNA and siRNA (Figure 1A and O’Connell et al., 2009).
The vector produced pre-miR-34a and mature miR-34a as dem-
onstrated by RNA blotting (Figure 1B) or RT-qPCR (Figure S1A
available online), in addition to GFP (Figure S1B). After transduc-
tion of murine bone marrow cells with miR-34a and control
vectors followed by reconstitution of lethally irradiated synge-
neic C57/B6 mice, we analyzed the recipient’s bone marrow
2 months later. GFP-positive cells were readily observed in
both the control and miR-34a-transduced marrow recipients
(hereafter referred to as ‘‘miR-34a mice’’; Figure 1C). Expression
of miR-34a was found to be elevated in primary bone marrowImmunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc. 49
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Figure 2. miR-34a Expression Causes an
Increase in Pro-B Cells and a Decrease in
Pre-B Cells
(A) Analysis of pro-B cells. Bone marrow cells
stained with CD19, c-kit, and IgM, analyzed by
flow cytometry. The left panels show representa-
tive histograms of the GFP+IgM compartment in
control (vector) and miR-34a-expressing mice.
In the right panel, individual dots represent the
percent of pro-B cells in the bone marrow of an
individual mouse, and the lines show the mean
percent of pro-B cells in mice from three indepen-
dent experiments (n = 12 for control and n = 10 for
miR-34a mice; t test, p = .0001).
(B) Analysis of pre-B cells. Bone marrow cells
stained with B220, IgM, and CD43 were analyzed
by flow cytometry. Left panels show representa-
tive histograms of the GFP+IgM compartment in
control and miR-34a-expressing mice. In the right
panel, individual dots represent the percent of pro-
B cells in the bone marrow of an individual mouse,
and the lines show the mean percent of pro-B cells
in mice from three independent experiments
(n = 14 for control and n = 10 for miR-34a mice;
t test, p = 0.0002).
(C) Assessment of miR-34a expression in
B-lineage cells at various stages of differentiation
collected by cell sorting. Bar graph shows miR-34a
expression (n = 2 samples; three independent
experiments were analyzed). Data shown repre-
sent mean ± SEM.
(D) Peripheral blood B lymphocytes in control and
miR-34a mice, with individual dots representing
the percent of B lymphocytes in individual mice
and the lines showing the mean percent of B cells
from three independent experiments (n = 11 for
vector control and n = 7 for miR-34a; p = 0.02).
(E) Enumeration of splenic B cells in miR-34a-
expressing mice. Individual dots represent the
percent of B cells among total spenocytes in indi-
vidual mice; lines represent the mean percent of B
cells in mice from three independent experiments
(n = 9 for vector control and n = 9 for miR-34a).
Immunity
mir-34a and Foxp1 in B Cell Developmentcells from the miR-34a mice (Figure 1D). The bone marrow was
stained with a combination of antibodies to delineate the various
hematopoietic lineages, including mature B cells (defined as
being CD19+IgM+), myeloid cells (CD11b+), T cells (CD33+),
and erythroid precursors (Ter119+). A significant reduction in
mature B cells, as a proportion of transduced cells (30% lower),
was observed (Figure 1E). We did not observe statistically signif-
icant changes in myeloid cells (Figure 1F), erythroid precursors
(Figure 1G), or T cells (Figure 1H). These differences were
observed consistently across three experiments. Thus, constitu-
tive expression of miR-34a causes a specific reduction in the
number of mature B cells.
miR-34a Expression Results in a Block in B Cell
Development at the Pro-B to Pre-B Cell Stage
in the Bone Marrow
To determine whether the observed reduction in mature B cells
was the consequence of a specific developmental abnormality
in B cell ontogeny, we performed flow cytometric analyses to
delineate the various stages of B cell maturation. We found50 Immunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc.a significant (2-fold) increase in pro-B cells (CD19+c-kit+IgM)
in miR-34a mice (Figure 2A). Conversely, there was a significant
reduction in pre-B cells (B220+CD43IgM) in miR-34a mice
(Figure 2B). This pattern indicates a developmental retardation
at the pro-B-cell-to-pre-B-cell transition when B cells are
passing through the pre-BCR checkpoint. A similar trend was
observed when alternate stains were used to delineate pro-B
cells (including CD19+CD43+AA4.1+ and CD43+B220+IgM)
and pre-B cells (CD19+CD25+IgM; data not shown). The
numbers of pro- and pre-B cells in miR-34a mice correlated
inversely with the expression pattern of miR-34a in the normal
B lineage cells, in which relatively high miR-34a was observed
at the pro-B cell stage with lower amounts in pre-B cells
(Figure 2C). A second miR-34a expressing vector, which uses
the native stem-loop structure and flanking regions and
produces mature miR-34a at lower amounts, induced a similar
phenotype (Figures S2A, S2C, and S2D). The decrease in bone
marrow B cells resulted in decreased circulating B lymphocytes
(Figure 2D), but splenic populations of B cells were largely
restored in miR-34a-overexpressing mice (Figure 2E). This
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Figure 3. Foxp1 Is a Bona Fide Target of miR-34a
(A) Schematic representation of Foxp1 cDNA and 30UTR
showing the conserved miR-34a seed region in its
30 UTR. Human and mouse miR-34a mature sequences
with proposed base pairing to the 30 UTR are presented
as is the mutant 30 UTR used in the luciferase assays
depicted in (B).
(B) Targeting of Foxp1 by miR-34a is via direct 30 UTR
interactions. Graphed is the relative luciferase activity of
293T extracts transfected with the designated luciferase-
30 UTR construct and mir-34a compared to cells trans-
fected with the luciferase-30UTR and empty vector,
normalized for transfection efficiency by a b-galactosidase
reporter. The following designations are for the various
30 UTRs attached to the luciferase reporter: antisense
2-mer, two copies of the miR-34a antisense sequence;
FOXP1mt, FOXP1 30 UTR with mutated mir-34a seed
site; BCL2mt, BCL2 30 UTR with mutated mir-34a seed
site; and no UTR, luciferase gene without a 30 UTR. Data
shown represent mean ± SD.
(C) FOXP1 expression, measured by RT-qPCR in NALM6
clones that express control vector (FUGW) or miR-34a
(FUGW/34a). Individual dots represent FOXP1 RNA levels
in individual clones, and the lines represent the mean
values in each case (t test, p = 0.0086).
(D) miR-34a expression, measured by RT-qPCR, in
NALM6 clones as in (C).
(E) Immunoblot analysis of murine Foxp1 in 70Z/3 cells
infected with MGP-34a versus vector alone. The numbers
below the blot indicate the relative expression level of the
protein as compared with the control. This experiment was
repeated twice with similar results.
(F) Assessment of FOXP1 expression in B lineage cells at
various stages of differentiation collected by cell sorting.
The bar graph shows FOXP1 expression (n = 2 samples;
two independent experiments were analyzed). Data
shown represent mean ± SEM.
(G and H) Foxp1 (G) and L32 (H) expression measured by
RT-qPCR in the bone marrow of mice reconstituted with
either vector- or miR-34a (n = 7 for vector, n = 8 for miR-
34a). t test, p = 0.0225 for comparison of Foxp1 expression
levels.
Immunity
mir-34a and Foxp1 in B Cell Developmentprobably represents homeostatic expansion of B cells in the
periphery by mechanisms that are independent of miR-34a
expression. Thus, interrupting the physiological downregulation
of miR-34a by constitutive expression results in a partial block in
B cell development.
Foxp1 Is a Bona Fide Target of miR-34a
To understand what targets of miR-34a might mediate the B cell
developmental block, we examined predicted targets by using
the TargetScan database (Lewis et al., 2003, 2005). From this
list of targets, we identified Foxp1, which is predicted to have
two 7-mer sites in the 30 UTR. Because Foxp1 has previously
been implicated in B cell development, we examined whether
this gene is a target of miR-34a. The 30 UTR of Foxp1 is schemat-
ically represented in Figure 3A, showing the more 50 of the two
conserved miR-34a sites. To determine whether Foxp1 might
represent a direct target of miR-34a, we performed luciferase
assays as previously described (O’Connell et al., 2008). Cells
cotransfected with pcDNA3-miR-34a and luciferase linked to
the FOXP1-30UTR showed repression of luciferase comparedto control (Figure 3B). When the conserved site in the FOXP1
30UTR was mutated (as depicted in Figure 3A), luciferase expres-
sion was derepressed (Figure 3B; FOXP1mt). As controls, we
examined repression of a UTR containing two repeats of the anti-
sense sequence to miR-34a (two repeats of antisense 22-mer),
which showed the greatest repression (Figure 3B, antisense
2-mer), as well as repression of a BCL2-30 UTR containing
construct, a previously reported miR-34a target (Figure 3B;
BCL2 and BCL2mt; Bommer et al., 2007). As negative controls,
we utilized the 30 UTR of two genes, Cebpb (encoding CEBPb)
and Sfpi1 (encoding PU.1), which were repressed by miR-155,
as well as a control luciferase construct with no UTR (Figure 3B
and O’Connell et al., 2008). We have also examined the second
UTR site that does not show repression in a similar assay (data
not shown).
To examine the effects of miR-34a expression on endogenous
Foxp1, we utilized two cell lines at a similar stage of differentia-
tion—NALM6, which is a human pre-B cell line, and 70Z/3, which
is a murine pre-B cell line. First, we assayed NALM6 single-cell
clones that had been transduced with a lentivector expressingImmunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc. 51
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Figure 4. Knockdown of Foxp1 Recapitu-
lates miR-34a-Induced B Lineage Cell
Abnormalities
(A) Schematic diagram showing the MGP-based
construct used for expressing the Foxp1 siRNA.
(B) The left panel shows Foxp1 RNA, measured
by RT-qPCR, in 70Z/3 cells infected with either
empty vector (Vector) or MGP-Foxp1si (Foxp1si).
The right panel shows immunoblot analysis of
Foxp1 in these cells. The numbers represent the
fold expression of Foxp1 at the protein level
compared to vector control. Data shown represent
mean ± SD.
(C) GFP expression in the bone marrow of mice
(vector and Foxp1si) 2 months after transplant,
measured by flow cytometry.
(D) Foxp1 expression in the bone marrow of mice
(vector and Foxp1si), as measured by RT-qPCR.
Individual dots represent Foxp1 RNA amounts in
individual mice, and the lines show the mean
amount for a representative experiment (n = 4 for
each group; t test, p = 0.0026). Experiments
were repeated three times, with similar trends in
all three experiments.
(E) Analysis of pro-B cells. Left panels show repre-
sentative histograms of the GFP+ IgM compart-
ment in control (vector) and Foxp1si mice. The
right hand panel shows pro-B cells as a percentage
of total GFP+ cells for a representative experiment,
with individual mice represented by individual dots
and the lines indicating the mean (n = 4 per group;
t test, p = 0.0004). Three independent experiments
showed similar trends.
(F) Analysis of pre-B cells. Left panels show
representative histograms of the GFP+ IgM
compartment in control and Foxp1si mice, below
which the percentage of cells in each of the four
quadrants is shown. The right panel shows pre-B
cells as a percentage of total GFP+ cells for a
representative experiment, with individual mice
represented by individual dots and the lines indi-
cating the mean (n = 4 per group; t test, p = 0.005).
Three independent experiments showed similar
trends.
Immunity
mir-34a and Foxp1 in B Cell DevelopmentmiR-34a (Figure S1C). This vector expressed GFP as well as
miR-34a by RNA blot analysis and RT-qPCR (Figures S1D–S1F).
Analysis of the single-cell clones revealed repression of FOXP1
and overexpression of miR-34a RNA (Figures 3C and 3D,
respectively). In murine 70Z/3 cells, we observed a similar
repression of Foxp1 at the protein level within 4 days of trans-
duction (Figure 3E). Analysis of Foxp1 RNA in B cell subsets
showed an inverse correlation with miR-34a amounts at the
pro- and pre-B cell stages (Figure 3F; compare with Fig-
ure 2C). Having observed repression of Foxp1 in cell lines, we
also examined Foxp1 mRNA expression in whole bone marrow
from miR-34a mice. Foxp1 mRNA is significantly downregulated
in the bone marrow of mice transduced with miR-34a (Fig-
ure 3G), with no significant change observed in L32 control
RNA (Figure 3H). It is notable that this difference was observed
in whole bone marrow, in which only approximately half of the52 Immunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc.cells had been transduced with miR-34a. Hence, repression of
Foxp1 by miR-34a is demonstrated in human and mouse cell
lines, as well as in primary murine bone marrow, and is mediated
through a conserved site in the 30 UTR of Foxp1.
Direct Repression of Foxp1 Recapitulates Constitutive
miR-34a Expression
Previous reports have indicated that the complete lack of
Foxp1 results in a profound B cell developmental block that
generates a near-total lack of mature B cells (Hu et al., 2006).
To examine whether the phenotype of miR-34a expression might
be explained by the repression of Foxp1, we developed
constructs to express a siRNA against Foxp1 (Foxp1si) in the
same format as the construct expressing miR-34a (Figure 4A).
Testing of this construct in 70Z/3 cells showed that Foxp1
mRNA was repressed 50%, similar to the repression observed
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Figure 5. Foxp1 Expression Rescues the miR-34a-
Induced B Cell Developmental Abnormality
(A) Schematic representation of the constructs used to
rescue miR-34a-mediated block in B cell development.
(B) Immunoblot analysis of extracts from 70Z/3 cells
infected with retroviruses depicted in (A). The numbers
represent relative expression of Foxp1, compared with
control.
(C) Expression of miR-34a as assayed by RT-qPCR in
70Z/3 cells infected with retroviruses (vector control
only, MGP-34a [miR-34a], MIG-Foxp1 [Foxp1], or MIG-
Foxp1+34a [Foxp1+34a]). Individual dots represent
measurements in individual mice, and the lines indicate
the means for each group (n = 4 per group; two indepen-
dent experiments were performed). Statistically significant
differences were found in the expression of miR-34a for
the following comparisons: vector versus miR-34a (t test,
p = 0.0001) and vector versus Foxp1+miR-34a (t test,
p = 0.0049).
(D) Expression of Foxp1 in the bone marrow, as assayed
by RT-qPCR, in mice receiving bone marrow transduced
with the same constructs as in (C), represented as fold
overexpression over control and normalized to L32. Indi-
vidual dots represent measurements in individual mice,
and the lines indicate the means for each group (n = 4
per group; two independent experiments were per-
formed). Statistically significant differences were found in
the expression of Foxp1 for the following comparisons:
vector versus Foxp1 (t test, p = 0.036) and vector versus
Foxp1+miR-34a (t test, p = 0.015).
(E) Expression of miR-34a in the bone marrow, as assayed
by RT-qPCR, in mice receiving bone marrow transduced
with the same constructs as in (C), shown as fold overex-
pression over control and normalized to 5S. Individual
dots represent measurements in individual mice, and the
lines indicate the means for each group (n = 4 per group;
two independent experiments were performed). Statisti-
cally significant differences were found in the expres-
sion of miR-34a for the following comparisons: vector
versus miR-34a (t test, p = 0.03) and vector versus
Foxp1+miR-34a (t test, p = 0.0056).
(F) Enumeration of pro-B cells (CD19+IgM-c-kit+) as
a percentage of total GFP+ cells for a representative
experiment (n = 4 per group; t test, p = 0.0048). Individual
dots represent measurements in individual mice, and the
lines indicate the means for each group. Two independent
experiments were performed.
(G) Enumeration of pre-B cells (B220+CD43IgM) as a percentage of total GFP+ cells for a representative experiment (n = 4 per group; t test, p = 0.0084). Indi-
vidual dots represent measurements in individual mice, and the bars indicate the means for each group. Two independent experiments were performed.
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mir-34a and Foxp1 in B Cell Developmentin miR-34a-expressing cells (Figure 4B). In addition, repression
by Foxp1si was similar to that by miR-34a at the protein level,
in which Foxp1 expression was reduced by 50% (Figure 4B,
right panel, compare to Figure 3E, right panel). Retroviral trans-
duction and bone marrow transfer showed a high degree of
reconstitution of the marrow by Foxp1si-expressing cells
(Figure 4C). Foxp1 RNA was reduced by 50% in the marrow
of mice reconstituted with this vector (Figure 4D). With this
degree of repression, a dramatic increase in pro-B cells (3.5-
fold) was observed (Figure 4E) along with a corresponding
decrease in pre-B cells (Figure 4F). In contrast, retrovirally medi-
ated knockdown of Bcl-2 in the bone marrow by a similar vector
failed to recapitulate the phenotype observed in the miR-34a-
overexpressing mice, despite the demonstration that Bcl-2 is
a direct target of miR-34a (Figures S3A and S3B). Instead, therewere major reductions in all stages of B cell differentiation and
a mild reduction in myeloid cells in the bone marrow (Figures
S3C–S3F). Hence, the block in B cell development is largely
recapitulated in a specific manner by the repression of Foxp1
with a siRNA.
Foxp1 cDNA Lacking Its 30 UTR Is Able to Rescue the
miR-34a-Mediated Block in B Cell Development
Next, we tested whether complementation of Foxp1 by an exog-
enous cDNA not responsive to miR-34a could correct the B cell
phenotype. MSCV-based constructs containing the Foxp1
coding sequence were generated with and without miR-34a
as depicted in Figure 5A, and the vector containing both miR-34a
and Foxp1 was designated as the ‘‘rescue vector.’’ These
constructs contained the entire coding sequence of Foxp1,Immunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc. 53
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Figure 6. Knockdown of miR-34a with a ‘‘Sponge’’ Strategy Is Effective and Results in Increased Mature B Cells in the Bone Marrow
(A) Schematic representation of the construct used to knockdown miR-34a expression. The backbone is the MGP vector described previously with the insertion
of ‘‘spacer miR-Target sites’’ downstream of the GFP. ‘‘34a-T’’ stands for miR-34a synthetic target site.
(B) Immunoblot analysis of extracts from 70Z/3 cells infected with retroviruses prepared from construct depicted in (A). The numbers represent relative expression
of Foxp1, compared with control.
(C–E) Luciferase assays demonstrate that the knockdown of miR-34a by the construct designated in (A) is specific for miR-34a target-containing 30 UTRs,
graphed as described for Figure 3B. Statistically significant differences were found in relative luciferase activity for the following comparisons: 34a versus
34a+anti-34as (Figure 6C, t test, p = 0.0053); control versus anti-34as (Figure 6D; t test, p = 0.0001); and 34a versus 34a+anti-34as (Figure 6D; t test,
p = 0.0033). Data shown represent mean ± SEM.
(F) Bone marrow flow cytometry plot showing that transduction results in the expression of GFP.
(G and H) Bone marrow flow cytometry plot showing GFP+ cells plotted for expression of CD19 and IgM. Bone marrow is from a mouse transduced with MGP
(‘‘Control’’; G), and a mouse transduced with MGP-anti-34as (H).
(I) Enumeration of mature B cells (CD19+IgM+) as a percentage of total GFP+ cells in mice receiving either control or the knockdown construct for miR-34a (n = 4
for control MGP; n = 8 for anti-34as; t test, p = 0.0285). Individual dots represent measurements in individual mice, and the lines indicate the means for each group.
Two independent experiments were performed.
(J) Foxp1 expression in bone marrow transductant mice receiving marrow with either MGP (‘‘Control’’) or anti-34as marrow (n = 4 for control MGP; n = 8 for
anti-34as; t test, p = 0.0022). Individual dots represent measurements in individual mice, and the lines indicate the means for each group. Two independent
experiments were performed.
Immunity
mir-34a and Foxp1 in B Cell Development
54 Immunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc.
Immunity
mir-34a and Foxp1 in B Cell Developmentfollowed by an internal ribosomal entry sequence (IRES) to allow
for GFP expression. The resultant constructs, when used to
infect 70Z/3 cells, overexpressed Foxp1 at the protein level,
at1.5–2 times endogenous levels (Figure 5B), and also overex-
pressed miR-34a (Figure 5C). Retroviral transduction and bone
marrow transfer was completed as before, and we detected
constitutive expression of Foxp1 RNA by RT-qPCR (Figure 5D).
In addition, miR-34a was constitutively expressed in mice
receiving the rescue vector, Foxp1+34a, in a quantitatively
similar manner to that observed when miR-34a was expressed
by itself (Figure 5E). In the bone marrow, pro-B cell numbers
were significantly decreased in animals receiving the rescue
vector as compared to those receiving miR-34a alone and similar
to pro-B cell numbers observed in the mice receiving the control
vector (Figure 5F). Similarly, pre-B cell numbers were compa-
rable to those in control mice, with a significant increase in
animals receiving the rescue vector compared with those
animals receiving miR-34a alone (Figure 5G). These findings indi-
cate that B cell maturation was largely rescued by provision of
Foxp1 lacking its 30 UTR in murine bone marrow. In contrast,
such an effect was not observed when BCL2 was utilized in
a similar ‘‘rescue experiment’’ (constructs depicted in Fig-
ure S5A). Despite BCL2 being a direct target of miR-34a and
the detection of transduced BCL2 in the bone marrow, the
number of pro-B cells remained elevated, and the number of
pre-B cells did not increase (Figures S5B–S5E). Hence, the
dependence of the miR-34a-mediated B cell phenotype on
Foxp1 is demonstrated in both loss-of-function and rescue
contexts, indicating that Foxp1 is a highly specific target of
miR-34a during B cell differentiation.
Knockdown of miR-34a Results in Increased Numbers
of Mature B Cells in the Bone Marrow
Our next step in understanding the role of miR-34a in B cells was
to analyze the effects of miR-34a loss of function. We did this by
attaching a ‘‘sponge’’ sequence to a reporter (Gentner et al.,
2009). In this approach, four consecutive synthetic miR-34a
target sequences separated by four 4-6-nucleotide spacer
sequences were cloned downstream of GFP in the previously
described MGP vector (MGP-anti-34as; Figure 6A and Table
S1). Retrovirus generated from this construct was used for trans-
duction of 70Z/3 cells, which were immunoblotted for Foxp1.
The cells expressing anti-34as showed a1.4-fold derepression
of Foxp1 at the protein level (Figure 6B and data not shown).
Luciferase assays performed with synthetic 34a target sites
(i.e., a perfectly complementary sequence; 34a-2-mer) as well
as the Foxp1 30 UTR in the reporter constructs demonstrated
derepression as a consequence of expression of anti-34as
(Figures 6C and 6D, respectively). This derepression was seen
both as an effect on endogenous miR-34a activity (left two
bars in Figures 6C and 6D) and an effect on exogenously overex-
pressed miR-34a (right two bars in Figures 6C and 6D). The
derepression was specific in that no derepression was seen
if there was no UTR in the reporter plasmid or an irrelevant(K) Enumeration of mature B cells (CD19+IgM+) as a percentage of total GFP+ ce
(n = 8 for control; n = 8 for MIG/Foxp1; t test, p = 0.0383). Individual dots represe
group. Two independent experiments were performed.UTR (Figure 6E and data not shown). Next, we utilized this
construct in a bone marrow transfer experiment and found
reproducible GFP expression in the recipient mice 2 months after
transfer (Figure 6F). Examination of the bone marrow revealed an
increase in the mature B cell population in mice with miR-34a
knockdown (Figure 6G compared with Figure 6H). These differ-
ences were statistically significant (Figure 6I). Minor differences
were seen in the pro-B and pre-B cell populations, but these
were not significant. In the bone marrow of mice transduced
with anti-34as, Foxp1 RNA levels were modestly but significantly
derepressed (Figure 6J). This set of findings is best explained by
the fact that pro-B and pre-B cells are transient states during B
cell development—cells flux through these states, accumulating
as mature B cells. The numbers of cells in these transient
compartments in miR-34a knockdown mice are therefore not
a sensitive measure of how rapidly cells are moving through
the compartment, whereas the number of mature B cells is
a more sensitive measure. Because Foxp1 RNA levels seem so
important in determining the course of B cell development, we
analyzed pooled data from two experiments in which we overex-
pressed Foxp1 (see Figure 5), finding that indeed, it is the mature
B cell pool (CD19+IgM+) that is increased upon modest overex-
pression of Foxp1 (Figure 6K). Thus, miR-34a knockdown
causes a phenotype that is the opposite of that seen with
constitutive expression, suggesting a role for miR-34a in the
physiological regulation of B cell development.
DISCUSSION
We describe here a role for miR-34a in B cell development that is
largely explained by its repression of Foxp1. The block induced
by miR-34a specifically involves Foxp1 because it is rescued by
Foxp1 expression and not expression of another miR-34a target,
BCL2. In early B cell development, loss of Foxp1 is known to
cause a block at the pro-B-cell-to-pre-B-cell transition, and
a near complete absence of B lymphocytes in the peripheral
lymphoid tissues (Hu et al., 2006). Additionally, Foxp1 downre-
gulation is essential to monocytic differentiation, indicating
a role in directing hematopoietic progenitors toward a B cell
fate and away from the myeloid fate (Shi et al., 2008; Shi et al.,
2004). By partial repression of Foxp1 in the bone marrow, consti-
tutive miR-34a expression slows passage through the pro-B-
cell-to-pre-B-cell transition, resulting in a lower number of circu-
lating B cells. Conversely, loss of miR-34a function results in
increased numbers of mature B cells (accompanied by modestly
elevated amounts of Foxp1), implying a less stringent or faster
transit through this checkpoint. The role of miR-34a and Foxp1
seem to be in controlling the output of the B cell developmental
pathway, with mature B cells being the most sensitive measure
of increased flux through this pathway. In differentiated B cells,
FOXP1 appears to act as a B cell oncogene, whose dysregulated
expression can be a consequence of translocations to the IGH
locus, in cases of marginal zone lymphoma, and through ampli-
fication in many cases of diffuse large B cell lymphoma (Lenzlls in mice receiving either control or constitutive expression contruct for Foxp1
nt measurements in individual mice, and the lines indicate the means for each
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mir-34a and Foxp1 in B Cell Developmentet al., 2008; Streubel et al., 2005; Wlodarska et al., 2005). Thus,
Foxp1 is both needed for B cell differentiation and a danger in
mature B cell life. We speculate that the effects of miR-34a on
Foxp1 may be the mode through which p53 suppresses this
potentially oncogenic protein in postgerminal center B cells.
Such an effect would parallel the previously described role of
miR-34a as a direct connection between the tumor suppressor
p53 and the oncogenic protein Bcl-2.
The effect of miR-34a on the B cell developmental pathway is
consistent with previously reported abnormalities seen with
a deficiency of p53, namely an increased number of pre-B cells
as well as B cells, with the latter finding also a consequence of
loss of miR-34a function (Lu and Osmond, 2000). With miR-34a
constitutively expressed, we find the opposite—an increase in
pro-B cells and a decrease in pre-B and B cells. Our findings
imply a connection between p53 and Foxp1 via the action of
miR-34a. In early B cell development, Foxp1 activates several
B cell factors, such as E2a and Pax-5, and binds to the
enhancers of the Rag genes (Hu et al., 2006). This activity of
Foxp1 may be dependent on the downregulation of miR-34a,
which releases repression of Foxp1, and allowing B cell develop-
ment to proceed. We interrupt this physiological downregula-
tion by constitutive expression, resulting in an accumulation of
pro-B cells. With miR-34a loss-of-function, mature B cells are
increased, probably arising from the loss of a miR-34a depen-
dent checkpoint. The idea that Foxp1 expression is important
for the output of B cells from the bone marrow is borne out by
the following: (1) reciprocal changes in Foxp1 levels are seen
with miR-34a gain- and loss-of-function, (2) mature B cells are
increased in the marrow of mice that overexpress Foxp1, and
(3) a partial arrest at the pro-B-cell-to-pre-B-cell transition is
found in Foxp1si-expressing mice.
The effects of miRNAs in B cell development have been
assessed globally as well as in terms of specific miRNAs. The
deletion of Dicer at the earliest stages of B cell development leads
to a block in development at the pro-B-cell-to-pre-B-cell transi-
tion (Koralov et al., 2008). In this case, bioinformatic analysis
showed that upregulated genes in Dicer-deficient B lineage
cells were likely to be those targeted by the miR-1792 cluster
and that ablation of the proapoptotic protein Bim (a target of
miR-1792) or transgenic overexpression of Bcl-2 could partially
rescue the developmental block. This target specificity is distinct
from the block induced by miR-34a because Bcl-2 increased
survival of miR-34a expressing pro-B cells but did not signifi-
cantly promote their differentiation. B cell developmental blocks
have also been seen after the disruption of specific miRNAs. Early
expression of miR-150 led to a block in B cell development,
whereas its deletion led to expansions of certain B cell subsets
(Xiao et al., 2007; Zhou et al., 2007). In this case, the relevant
target appeared to be c-Myb, a transcription factor involved in
many stages of lymphocyte differentiation. Overexpression of
the miR-1792 cluster led to a B-lymphoproliferative disease,
probably as a consequence of suppression of the tumor
suppressor gene PTEN and Bim (Xiao et al., 2008). Other miRNAs
with effects of B cell development include miR-181a and
miR-155, which promote early B cell development and the
germinal center response, respectively (Chen et al., 2004; Rodri-
guez et al., 2007; Thai et al., 2007; Vigorito et al., 2007). Specific
targeting by miR-155 in the context of B cell development has56 Immunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc.been extensively investigated and it appears that multiple targets
are responsible for miR-155-induced phenotypes (Chen et al.,
2008; Pedersen et al., 2008; Vigorito et al., 2007).
The specificity of miRNA targeting remains incompletely
understood. On the one hand, miRNAs, including miR-34a,
are predicted to target hundreds of genes by computational
algorithms. On the other hand, in particular developmental
contexts, one or a few genes are most important in the causa-
tion of a miRNA-mediated phenotype. Such observations
have been made in both loss-of-function and gain-of-function
contexts, indicating the general applicability of this principle
for particular miRNAs. Our study extends these observations
by demonstrating a specificity of miR-34a targeting for Foxp1
in early B lymphoid development. This is based on both reca-
pitulation and rescue of the phenotype by Foxp1 loss and
gain of function, respectively. The basis of such specificity is
likely the fact that certain cell fate decisions hinge on small
changes in the expression of critical lineage specification
genes, and miRNAs can cause such changes. From this, it
can be inferred that the study of miRNAs in hematopoietic
development may illuminate critical points in cell fate decisions
and bring novel insights into this complex and dynamic devel-
opmental system.
Our findings may be of relevance in human disease as others
have observed that miR-34a is functionally lost (either directly or
as a consequence of p53 deletion) in chronic lymphocytic
leukemia but is overexpressed in acute myeloid leukemia (Isken
et al., 2008; Mraz et al., 2009; Zenz et al., 2009). In our study,
overexpression of miR-34a led to disruptions in B cell develop-
ment, but not myeloid development. We have confirmed
independently that miR-34a is overexpressed in AML by
RT-qPCR (data not shown) and that its overexpression does
not correlate with that of miR-155. Given that we did not observe
a myeloproliferative disorder in miR-34a-overexpressing mice,
any mechanism whereby miR-34a contributes to leukemia is
likely to be distinct from that observed in miR-155-expressing
mice (O’Connell et al., 2008). Our findings suggest one possi-
bility—the expression of miR-34a may affect the phenotype of
the leukemic cells by blocking cells transformed by other onco-
genic lesions from differentiating into B lineage cells. Indeed,
some recent studies indicate that there may be a progenitor
with lymphoid characteristics that gives rise to acute myeloid
leukemia (Deshpande et al., 2006). Our results suggest that
miRNA expression may be one mechanism whereby the
leukemia assumes a distinctive lymphoid or myeloid phenotype.
Such phenotypic specification certainly has clinical relevance,
given that acute myeloid leukemia in general remains the more
difficult of the acute leukemias to treat. However, further work
needs to be done to understand the role that miR-34a plays in
leukemia and how its action or inhibition can be parlayed into
novel therapeutic strategies.
EXPERIMENTAL PROCEDURES
Cell Culture
All cells were cultured in a sterile incubator maintained at 37C with 5% CO2.
293T cells were cultured in complete DMEM with 10% FBS, 100 units/ml peni-
cillin, and 100 units/ml streptomycin. WEHI-231 and 70Z/3 cells were cultured
in complete RPMI with 10% FBS, 100 units/ml penicillin, 100 units/ml strepto-
mycin, and 50 mM 2-Mercaptoethanol.
Immunity
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The MGP vector system has been described previously, and further detailed
cloning strategies are available upon request (O’Connell et al., 2009). Table
S1 contains sequence information for all oligonucleotides used for building
new constructs. MiR-34a and siRNAs were built with the Invitrogen BlockiT
pol II miR RNAi strategy as described previously, with the miR-155 arms for
processing (O’Connell et al., 2009). SiRNA sequences were predicted with
the Invitrogen BlockiT miR RNAi designer. In addition, a 300 base pair
sequence of human genomic DNA encoding the native miR-34a mature
sequence, endogenous stem-loop structure, and flanking sequences was
PCR-amplified with the 34a.NotI.f and 34a.XhoI.r primers and cloned into
the MGP vector with the NotI and XhoI sites, as well as into pcDNA3 with
34a.EcoRI.f and 34a.XhoI.r primers and cloned into the EcoRI and XhoI
sites. The MGP-based vector is referred to as MGP-miR-34a-lo. The last
set of expression vectors, utilized for expression of miR-34a in human cell
lines, was developed from the FUGW vector system (Lois et al., 2002).
For this purpose, miR-34a genomic sequence was cut out of pcDNA3-34a
and blunt-ligated into the FUGW EcoRI site. For reporter assays, two
regions of the FoxP1 30 UTR were amplified by PCR, each containing a puta-
tive miR-34a binding site as determined by TargetScan (Lewis et al., 2005).
The 50 segment was 637 base pairs and the 30 segment was 760 base pairs.
A total of 2000 base pairs of the BCL2 30 UTR was also PCR-amplified.
These PCR products were cloned into pmiReport (Ambion). We mutated
the miR-34a seed regions in both the FoxP1 30UTR 50 segment and the
BCL2 30 UTR segment with PCR to yield Foxp1mt and BCL2mt constructs.
A positive control insert consisting of two miR-34a antisense sites (antisense
2-mer) was constructed by annealing oligonucleotides with SpeI and HindIII
sticky ends and cloning them into pmiReport. For the rescue vectors,
cDNAs for Foxp1 and BCL2 were PCR-amplified from pCMV-Sport-Foxp1
(Open Biosystems) and pDNR-Dual-BCL2 (Harvard PlasmID Core Facility)
and cloned between the BglII and XhoI sites in MSCV-IRES-GFP, yielding
MIG/Foxp1 and MIG/BCL2, respectively. The cDNAs contain the entire
coding sequence for Foxp1 (listed in Table S1) and BCL2, respectively.
miR-34a was cloned by PCR amplification from pcDNA3-34a and cloned
between the XhoI and EcoRI sites in the MIG vectors, yielding MIG/
Foxp1+34a and MIG/BCL2+34a vectors, respectively. The MGP/anti-34as
construct was generated by annealing the 34a-spacer-f and 34a-spacer-r
oligonucleotides (designed with XhoI/NotI sticky ends) and ligating them
into the MGP vector with XhoI and NotI. The spacers between each miR-
34a binding site were the same as those previously published (Gentner
et al., 2009).
Mice and Bone Marrow Reconstitution Experiments
C57BL/6 mice were bred and housed in the Caltech Office of Laboratory
Animal Resources (OLAR) facility. The Caltech Institutional Animal Care and
Use Committee (IACUC) approved all experiments related to mice. Virus
production and reconstitution experiments were performed as previously
described (O’Connell et al., 2008). Experimental groups of four to five mice
received each of the vectors described. Recipient mice were monitored for
health and a peripheral blood sample removed at 1 month for flow cytometric
analysis. Mice were sacrificed 2 months after reconstitution and were exam-
ined by morphology, FACS and RT-qPCR as described below. All experiments
were repeated at least twice and in most cases, three times, as described in
figure legends.
Flow Cytometry
Cells were isolated from the relevant tissue and homogenized, and red
blood cells were lysed with RBC lysis buffer (Biolegend). Cells were stained
with the following Fluorophore-conjugated antibodies (all from Ebioscience):
CD33, CD11b, CD19, B220, CD43, CD117 (c-kit), CD25, IgM, Gr-1, Ter-119,
AA4.1, CD4, and CD8a, in various combinations to delineate the hematopoi-
etic lineages and various stages of B cell differentiation. Cells were sorted
with a FACSCalibur (Becton Dickinson) and all data were analyzed with
FloJo software (Treestar). Specific gating strategies to delineate various B
cell populations are available upon request. Data were presented as the
percentage of GFP-positive cells in the relevant hematopoietic compartment.
These data were also compared against the GFP-negative cells within the
same mouse.Cell Sorting for RNA Analysis at Various Stages of B Cell
Differentiation
The bone marrow was extracted from two mice, lysed in RBC lysis buffer, and
spun down. Cells were then resuspended in lymphocyte FACS buffer (13
Hanks Buffered Salt Solution, 10mM HEPES, and 2.5 mg/mL BSA), filtered
through a 40 mm mesh, blocked with FcBlock (Becton Dickinson), and
depleted on a magnetic column for CD11b, Gr-1, Ter119, CD33, and NK1.1
with biotinylated antibodies and streptavidin-MACS beads, as per the manu-
facturer’s instructions (Miltenyi). Cells were then stained with c-kit, B220,
CD43, IgM, Streptavidin, and CD138 and sorted on a BD Biosciences
FACSVantage flow cytometer (Caltech Core facility). Four populations
of cells were collected: Lin (B220IgMStreptavidinCD138); pro-B
cells (c-kit+B220+CD43+IgMstreptividin), pre-B cells (B220+CD43c-kit
IgMstreptavidin) and B cells (B220+c-kitCD43IgM+strepatavidin).
RNA was isolated by TRIzol (Invitrogen) purification and subjected to RT-
qPCR as described below. These sorts were repeated three times, with similar
results.
Sequence Alignments
The miR-34a seed region and Foxp1 30 UTR sequences from human (Homo
sapiens), mouse (Mus musculus), rat (Rattus norvegicus), and frog (Xenopus
tropicalis) were obtained and aligned with TargetScan (Lewis et al., 2005).
Experiments with Cell Lines
VSV-G-pseudotyped FUGW lentiviruses were made with TransIT-293-based
transient transfections of 293T cells. The viruses were then used for infecting
NALM6 human pre-B cells by spin infection at 1,200 3 g for 90 min at 30C,
supplemented with 10 mg/mL polybrene (Chemicon). Single-cell clones were
derived by subjecting the cells to limiting dilution assays. Clones were main-
tained in RPMI supplemented with 10% FBS and antibiotics. For examination
of Foxp1 levels in murine cells, MSCV-based retroviruses were prepared as
described previously, pseudotyped with pCL-Eco, and used for infecting
70Z/3 murine pre-B cells. Cells were expanded for 3–4 days and then utilized
for RNA purification or protein extraction for immunoblotting.
Luciferase Reporter Assays
A total of 2 3 105 293T cells were cultured for 18 hr and subsequently trans-
fected with relevant plasmids with TransIT 293. Transfected plasmids included
pcDNA3, pcDNA3-34a, b-gal expression vector, and pmiReport vectors. For
the derepression assays with the sponge construct, we added in MGP (empty
vector) or MGP/anti-34as. After 48 hr, cells were lysed with Reporter Lysis
Buffer (Promega) and subjected to luciferase reporter assays as previously
described (O’Connell et al., 2008).
RNA Preparation and Quantitation
RNA was isolated with TRIzol as per the manufacturer’s instructions. We per-
formed SYBR Green-based quantitative real-time PCR (qPCR) with a 7300
Real-Time PCR system (Applied Biosystem) to assay miR-34a, 5s, FoxP1
mRNA,BCL2mRNA, and L32 mRNA levels as described previously (O’Connell
et al., 2008). Mature miR-34a and 5s RNA were assayed with a miRVana
miRNA detection kit as per the manufacturer’s instructions (Ambion). Human
FOXP1, BCL2, and L32 mRNA were detected with specific primers and
utilizing the SYBR Green system (Applied Biosystems) (Table S1).
Immunoblotting
Total cell extracts were fractionated by electrophoresis on a 10% SDS poly-
acrylamide gel and electroblotted on to a Trans-Blot nitrocellulose membrane
(Bio-Rad, Hercules, CA) with a semidry transfer apparatus (Bio-Rad). Protein
detection was performed with the following antibodies: FoxP1 (ab16645)
(Abcam, Cambridge, MA), b-Actin (A1978) (Sigma), GAPDH (sc-47724),
a-Tubulin (sc-5286), goat anti-mouse HRP-conjugated secondary antibody
(sc-2005), and goat anti-rabbit HRP-conjugated secondary antibody (sc-
2004) (Santa Cruz Biotechnology). Expression intensities were determined
with Scion Image software.
Statistical Tests
All statistical analyses were performed with Microsoft Excel. Expression and
flow cytometric data were first analyzed by an F-test for determining whetherImmunity 33, 48–59, July 23, 2010 ª2010 Elsevier Inc. 57
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mir-34a and Foxp1 in B Cell Developmentthe distributions were homo- or heteroscedastic. Then, the correct type of
unpaired, two-tailed t test was applied to determine whether the distributions
were statistically different. t tests that returned p values of less than 0.05 were
considered to be statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and can be found
with this article online at doi:10.1016/j.immuni.2010.06.013.
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